Cargando…

Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma

BACKGROUND: Child-Turcotte-Pugh (CTP) score is the standard tool to assess hepatic reserve in hepatocellular carcinoma (HCC), and CTP-A is the classic group for active therapy. However, CTP stratification accuracy has been questioned. We hypothesized that plasma insulin-like growth factor 1 (IGF-1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaseb, Ahmed O., Xiao, Lianchun, Hassan, Manal M., Chae, Young Kwang, Lee, Ju-Seog, Vauthey, Jean-Nicolas, Krishnan, Sunil, Cheung, Sheree, Hassabo, Hesham M., Aloia, Thomas, Conrad, Claudius, Curley, Steven A., Vierling, John M., Jalal, Prasun, Raghav, Kanwal, Wallace, Michael, Rashid, Asif, Abbruzzese, James L., Wolff, Robert A., Morris, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085880/
https://www.ncbi.nlm.nih.gov/pubmed/24815863
http://dx.doi.org/10.1093/jnci/dju088
_version_ 1782324724098924544
author Kaseb, Ahmed O.
Xiao, Lianchun
Hassan, Manal M.
Chae, Young Kwang
Lee, Ju-Seog
Vauthey, Jean-Nicolas
Krishnan, Sunil
Cheung, Sheree
Hassabo, Hesham M.
Aloia, Thomas
Conrad, Claudius
Curley, Steven A.
Vierling, John M.
Jalal, Prasun
Raghav, Kanwal
Wallace, Michael
Rashid, Asif
Abbruzzese, James L.
Wolff, Robert A.
Morris, Jeffrey S.
author_facet Kaseb, Ahmed O.
Xiao, Lianchun
Hassan, Manal M.
Chae, Young Kwang
Lee, Ju-Seog
Vauthey, Jean-Nicolas
Krishnan, Sunil
Cheung, Sheree
Hassabo, Hesham M.
Aloia, Thomas
Conrad, Claudius
Curley, Steven A.
Vierling, John M.
Jalal, Prasun
Raghav, Kanwal
Wallace, Michael
Rashid, Asif
Abbruzzese, James L.
Wolff, Robert A.
Morris, Jeffrey S.
author_sort Kaseb, Ahmed O.
collection PubMed
description BACKGROUND: Child-Turcotte-Pugh (CTP) score is the standard tool to assess hepatic reserve in hepatocellular carcinoma (HCC), and CTP-A is the classic group for active therapy. However, CTP stratification accuracy has been questioned. We hypothesized that plasma insulin-like growth factor 1 (IGF-1) is a valid surrogate for hepatic reserve to replace the subjective parameters in CTP score to improve its prognostic accuracy. METHODS: We retrospectively tested plasma IGF-1 levels in the training set (n = 310) from MD Anderson Cancer Center. Recursive partitioning identified three optimal IGF-1 ranges that correlated with overall survival (OS): greater than 50ng/mL = 1 point; 26 to 50ng/mL = 2 points; and less than 26ng/mL = 3 points. We modified the CTP score by replacing ascites and encephalopathy grading with plasma IGF-1 value (IGF-CTP) and subjected both scores to log-rank analysis. Harrell’s C-index and U-statistics were used to compare the prognostic performance of both scores in both the training and validation cohorts (n = 155). All statistical tests were two-sided. RESULTS: Patients’ stratification was statistically significantly stronger for IGF-CTP than CTP score for the training (P = .003) and the validation cohort (P = .005). Patients reclassified by IGF-CTP relative to their original CTP score were better stratified by their new risk groups. Most important, patients classified as A by CTP but B by IGF-CTP had statistically significantly worse OS than those who remained under class A by IGF-CTP in both cohorts (P = .03 and P < .001, respectively, from Cox regression models). AB patients had a worse OS than AA patients in both the training and validation set (hazard ratio [HR] = 1.45, 95% confidence interval [CI] = 1.03 to 2.04, P = .03; HR = 2.83, 95% CI = 1.65 to 4.85, P < .001, respectively). CONCLUSIONS: The IGF-CTP score is simple, blood-based, and cost-effective, stratified HCC better than CTP score, and validated well on two independent cohorts. International validation studies are warranted.
format Online
Article
Text
id pubmed-4085880
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-40858802014-07-08 Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma Kaseb, Ahmed O. Xiao, Lianchun Hassan, Manal M. Chae, Young Kwang Lee, Ju-Seog Vauthey, Jean-Nicolas Krishnan, Sunil Cheung, Sheree Hassabo, Hesham M. Aloia, Thomas Conrad, Claudius Curley, Steven A. Vierling, John M. Jalal, Prasun Raghav, Kanwal Wallace, Michael Rashid, Asif Abbruzzese, James L. Wolff, Robert A. Morris, Jeffrey S. J Natl Cancer Inst Article BACKGROUND: Child-Turcotte-Pugh (CTP) score is the standard tool to assess hepatic reserve in hepatocellular carcinoma (HCC), and CTP-A is the classic group for active therapy. However, CTP stratification accuracy has been questioned. We hypothesized that plasma insulin-like growth factor 1 (IGF-1) is a valid surrogate for hepatic reserve to replace the subjective parameters in CTP score to improve its prognostic accuracy. METHODS: We retrospectively tested plasma IGF-1 levels in the training set (n = 310) from MD Anderson Cancer Center. Recursive partitioning identified three optimal IGF-1 ranges that correlated with overall survival (OS): greater than 50ng/mL = 1 point; 26 to 50ng/mL = 2 points; and less than 26ng/mL = 3 points. We modified the CTP score by replacing ascites and encephalopathy grading with plasma IGF-1 value (IGF-CTP) and subjected both scores to log-rank analysis. Harrell’s C-index and U-statistics were used to compare the prognostic performance of both scores in both the training and validation cohorts (n = 155). All statistical tests were two-sided. RESULTS: Patients’ stratification was statistically significantly stronger for IGF-CTP than CTP score for the training (P = .003) and the validation cohort (P = .005). Patients reclassified by IGF-CTP relative to their original CTP score were better stratified by their new risk groups. Most important, patients classified as A by CTP but B by IGF-CTP had statistically significantly worse OS than those who remained under class A by IGF-CTP in both cohorts (P = .03 and P < .001, respectively, from Cox regression models). AB patients had a worse OS than AA patients in both the training and validation set (hazard ratio [HR] = 1.45, 95% confidence interval [CI] = 1.03 to 2.04, P = .03; HR = 2.83, 95% CI = 1.65 to 4.85, P < .001, respectively). CONCLUSIONS: The IGF-CTP score is simple, blood-based, and cost-effective, stratified HCC better than CTP score, and validated well on two independent cohorts. International validation studies are warranted. Oxford University Press 2014-05-08 /pmc/articles/PMC4085880/ /pubmed/24815863 http://dx.doi.org/10.1093/jnci/dju088 Text en © The Author 2014. Published by Oxford University Press. http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Article
Kaseb, Ahmed O.
Xiao, Lianchun
Hassan, Manal M.
Chae, Young Kwang
Lee, Ju-Seog
Vauthey, Jean-Nicolas
Krishnan, Sunil
Cheung, Sheree
Hassabo, Hesham M.
Aloia, Thomas
Conrad, Claudius
Curley, Steven A.
Vierling, John M.
Jalal, Prasun
Raghav, Kanwal
Wallace, Michael
Rashid, Asif
Abbruzzese, James L.
Wolff, Robert A.
Morris, Jeffrey S.
Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
title Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
title_full Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
title_fullStr Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
title_full_unstemmed Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
title_short Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
title_sort development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085880/
https://www.ncbi.nlm.nih.gov/pubmed/24815863
http://dx.doi.org/10.1093/jnci/dju088
work_keys_str_mv AT kasebahmedo developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT xiaolianchun developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT hassanmanalm developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT chaeyoungkwang developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT leejuseog developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT vautheyjeannicolas developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT krishnansunil developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT cheungsheree developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT hassaboheshamm developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT aloiathomas developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT conradclaudius developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT curleystevena developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT vierlingjohnm developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT jalalprasun developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT raghavkanwal developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT wallacemichael developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT rashidasif developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT abbruzzesejamesl developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT wolffroberta developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma
AT morrisjeffreys developmentandvalidationofinsulinlikegrowthfactor1scoretoassesshepaticreserveinhepatocellularcarcinoma